Skip to main content
Poxel logo

Poxel — Investor Relations & Filings

Ticker · POXEL ISIN · FR0012432516 LEI · 9695003OIX0T7NX72N26 PA Professional, scientific and technical activities
Open in API
Filings indexed 470 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country FR France
Listing PA POXEL

About Poxel

https://www.poxelpharma.com/en_us

Poxel is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The company's pipeline features two mid-stage candidates: PXL065, a deuterium-stabilized R-pioglitazone for NASH that has completed a Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator for rare diseases. Additionally, Poxel's product TWYMEEG® (Imeglimin) is approved and marketed in Japan by Sumitomo Pharma for the treatment of type 2 diabetes, providing the company with royalties and sales-based payments.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 85% confidence The document is a mandatory regulatory disclosure under French law (AMF Article 223-16 and Code de Commerce) providing the total number of shares and voting rights as of a given date. It does not announce a specific financing or share issue, nor is it a shareholder vote result, annual or interim report, or proxy material. It is a general regulatory filing of share capital/voting rights information, fitting the fallback category. Therefore, it should be classified as a general Regulatory Filing (RNS).
2026-05-13 French
Informations privilégiées / Autres communiqués
Regulatory Filings
2026-04-30 French
Inside Information / Other news releases
Regulatory Filings
2026-04-30 English
Inside Information / Operations of the issuer (acquisitions, sales...)
Capital/Financing Update Classification · 82% confidence The document is a press release announcing Poxel’s definitive agreement to sell its drug candidate PXL770 to Scynexis, detailing upfront payments and milestone payments. This is a financing transaction rather than an earnings update or regulatory report. It describes a capital‐raising/asset‐sale arrangement (upfront and milestone payments), so it best fits under “Capital/Financing Update” (CAP).
2026-03-31 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Regulatory Filings Classification · 72% confidence The document is a press release announcing the sale/licensing of an asset (the PXL770 candidate drug) and associated milestone payments. It is not an AGM presentation, earnings release, or financial report, nor is it a share issue, director dealing, dividend notice, or merger/takeover. There is no dedicated category for licensing transactions, so it falls into the miscellaneous “Regulatory Filings” fallback category.
2026-03-31 French
Inside Information / News release on accounts, results
Capital/Financing Update Classification · 95% confidence The document is a press release providing detailed information on a new drawdown under a Tranche D PDR bond financing, outlining terms (interest rates, fees, collateral, availability period) and planned issuances, clearly relating to fundraising and capital structure adjustments rather than an earnings release or regulatory filing. This fits the definition of a Capital/Financing Update (CAP).
2026-03-25 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.